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Twoyearsago,inaneditorial[1]sparked
by the revelations from PLoS Medicine and
The New York Times’ intervention in litigation
relating to Prempro [2], we wrote that ‘‘the
story told in these documents amounts to
one of the most compelling expositions ever
seen of the systematic manipulation and
abuse of scholarly publishing by the phar-
maceutical industry and its commercial
partners in their attempt to influence the
health care decisions of physicians and
the general public.’’ In the first scholarly
examination of these documents, published
late last year [3], Adriane Fugh-Berman
concluded that ‘‘marketing messages in
credible journals have almost certainly
contributed to widespread use of hormone
replacement therapy among millions of
women who had no medical indication for
the drug’’ – a statement that suggests the
medical literature had been acting in direct
contradiction of the first ethical rule of all
physicians, to ‘‘first, do no harm.’’
Over the past month PLoS Medicine has
published three articles that bring new
perspectives to the problem of ghostwrit-
ing. These perspectives and the possible
remedies that two of them offer need
serious consideration in light of two recent
conferences [4,5] and other evidence sug-
gesting that, in stark contrast to the pro-
testations of many in the pharmaceutical
and medical writing industries, ghostwrit-
ing and its larger relation, ghost-manage-
ment, of the medical literature remain key
tactics deployed by pharmaceutical com-
panies, and that current attempts to
reduce the practices are not succeeding.
The first article, by Simon Stern and
Trudo Lemmens [6], takes a novel legal
perspective and suggests that legal sanc-
tions could be applied. They argue that a
‘‘guest author’s claim for credit of an
article written by someone else constitutes
legal fraud’’ and that, in addition, ‘‘The
same fraud could support claims of ‘fraud
on the court’ against a pharmaceutical
company that has used ghostwritten arti-
cles in litigation.’’ These are potentially
very serious charges that could be laid at
the door of ghost and guest authors and
their employers.
The second article, by medical writer
Alastair Matheson [7], takes a critical look
at the rules of authorship for medical
journals, as laid down by the International
Committee for Medical Journal Editors
(ICMJE). On the basis of over 20 years’
experience in the medical communications
sector, he says that, in clear contrast to
their intention, the authorship standards
have been subverted and are being used
by the pharmaceutical industry to make
ghostwriting almost legitimate (note: PLoS
Medicine is not a member of the ICMJE; we
follow some of its guidelines, including
those on authorship). His remedy involves
fundamental revisions of the ICMJE guide-
lines, including the concept of origination
being given comparable importance to
authorship and contributorship, and that
writers and companies who work on in-
dustry publications should be listed as
byline authors.
Such remedies merit serious consider-
ation, because there is no evidence that
ghostwriting in the medical literature has
abated; the third of the articles in PLoS
Medicine this month [8] from someone with
direct involvement in ghostwriting is un-
usual only because it’s an example of a
ghostwriter going on record. Linda Logd-
berg describes the nuts and bolts of how
ghostwriting happens and how, as a pro-
fessional medical writer in the early 2000s,
she participated in it until she came across
an example that clashed with her personal
beliefs.
Other evidence that has come to light
indicates that PLoS Medicine itself is not
immune. First, in October 2010, Philip
Davis, writing on the Society of Scholarly
Publishers blog [9], asserted that an ano-
nymous ghostwriter he had interviewed
claimed to have published in many leading
medical journals, including PLoS Medicine.
(We asked Philip Davis to provide details of
the papers in PLoS Medicine. He replied that
he could not, as the ghostwriter had spoken
on condition of anonymity, and to provide
the details ofthe articles would compromise
that anonymity). Second, a study by JAMA
[10], reported at the Peer Review Con-
gress in 2009 (but not yet published), that
involved interviewing authors of papers
published in six top medical journals,
including PLoS Medicine, showed that 7.8%
of authors from 630 articles admitted that
they had lied in their authorship statements
and that, in complete opposition to journal
policies, had included authors who did not
qualify for authorship according to guide-
lines (i.e., were guest authors) orhad left out
authors who should have been included
(ghost authors). The crucial point here is
that, in contrast to the documents arising
from litigation such as in the PremPro case,
all these accounts are recent, documenting
specific examples arising in the past 5–10
years or possibly even more recently (PLoS
Medicine is not yet 7 years old).
Such anecdotes add to the body of
evidence that the medical literature con-
tinues to be systematically manipulated
to promote specific products. There was
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writing picture – that of how medical
journals benefit [11]. Last year PLoS
Medicine published an article that laid out
how journals potentially benefit from
ghostwritten articles. In their paper, Peter
Gøtzsche and colleagues concluded that
some journals derived substantial income
from industry-funded trials and that
industry-funded trials were in fact more
likely to be cited than non-industry trials.
The authors noted evidence showing that
‘‘sponsoring companies may employ var-
ious strategies to increase the awareness of
their studies, including ghost authored
reviews that cite them.’’ Journals have no
more precious currency than citations.
‘‘Medicine, as a profession, must take
responsibility for this situation. Naı ¨vete ´i s
no longer an excuse … physician-investi-
gators should create and uphold a stan-
dard where relationships with industry are
regarded as unsavory rather than sought
after’’ [3]. This is what Adriane Fugh-
Berman concluded in her article last year.
To this we would add that journals too
must take responsibility for their actions
and start to think creatively about possible
solutions, starting perhaps with those posed
by Stern, Lemmens, and Matheson.
But, to be clear, the problem lies deeper
than terminology. Everyone involved in
the medical publishing industry, including
journals, institutions, and the bodies that
oversee research, need to take specific
action to eradicate the seemingly endemic
corrupt authorship practices that remain
within the medical literature—starting by
accepting the extent of the problem.
Without such action, the already appar-
ently shaky trust held by the public for the
medical literature may become irrevocably
damaged.
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